MEDIUM confidence: 100% data completeness, but the composite (36) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $810M— | $587M-27.5% | $788M+34.1% | $705M-10.5% | $944M+33.9% |
| EPS (dil.) | $-0.20— | $-1.90n/m | $-2.56n/m | $-3.04n/m | $-2.38n/m |
| Free Cash Flow | $13M— | -$294M-2383.1% | -$336Mn/m | -$546Mn/m | -$320Mn/m |
| Gross Margin | 98.7% | 97.6%-1.1pp | 98.8%+1.2pp | 98.4%-0.4pp | 98.3%-0.1pp |
| Operating Margin | -3.7% | -69.8%-66.1pp | -44.9%+24.9pp | -67.4%-22.5pp | -40.5%+26.9pp |
| Net Margin | -3.5% | -45.9%-42.4pp | -46.5%-0.6pp | -64.4%-17.9pp | -40.4%+24.0pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Avg target $93 (last qtr, 12 analysts) → $91 (last mo, 3) (-2.6%).
Buy-rated share 78% → 83% over ~3 months (+5pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $-1.08 | $-0.69 | +36.1% |
| Apr 2026 | $-0.85 | $-0.56 | +34.1% |
| Feb 2026 | $-1.24 | $-1.41 | -14.0% |
| Oct 2025 | $-1.15 | $-0.61 | +47.0% |
| Jul 2025 | $0.27 | $0.86 | +218.5% |
| Apr 2025 | $-1.11 | $-0.75 | +32.4% |
| Feb 2025 | $-1.09 | $-0.66 | +39.4% |
| Nov 2024 | $-1.16 | $-0.95 | +18.1% |
Net insider -$26.0M over 180 days (2 open-market buys, 26 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
The QScore of 36 indicates a neutral outlook for Ionis Pharmaceuticals, with the long-term and short-term scores showing minimal divergence. The stock scores high on growth, driven by strong revenue and free cash flow growth of 33.9% and 41.4%, respectively. However, it is held back by poor profitability, with a negative ROE of -110.8% and operating margin of -68.1%, as well as a relatively low value score due to its EV/EBITDA of 2.6 and negative P/E.